Release
Details

CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, announced that two scientific abstracts have been accepted for presentation at the 21^st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 16-19, 2018, in Chicago.

The first presentation will share information relating to Intellia’s lead in vivo program, for transthyretin amyloidosis. The data being presented include results from an ongoing collaboration with researchers at the University of Porto in Portugal. The second presentation will focus on Intellia’s ongoing research collaboration with IRCCS Ospedale San Raffaele in Italy to develop CRISPR-edited, T-cell therapies to address hard-to-treat cancers. Intellia will also participate in an education session on RNA therapeutics.

Details of Intellia’s presentations are as follows:

• “Rescue of Amyloid Deposition Phenotype after Single-Treatment CRISPR/Cas9 Gene Editing in a Humanized Mouse Model of TTR Amyloidosis”
  Session: Neurologic Diseases (Including Ophthalmic and Auditory Diseases) I
  Session date/time:Wed., May 16, 2018, 5:30-7:30 p.m. CT
  Location: Stevens Salon C, D

• “Hunting WT1-Specific T-Cell Receptors for TCR Gene Editing for Acute Myeloid Leukemia”
  Session: Cancer – Immunotherapy, Cancer Vaccines I
  Session date/time:Wed., May 16, 2018, 5:30-7:30 p.m. CT
  Location: Stevens Salon C, D

• “Lipid Nanoparticle-Based RNA Delivery: At the Intersection of Chemistry and Immunology”
  Presenter: Jonathan Finn, Ph.D., executive director, Platform Biology
  Session: Education Session 401 – RNA Therapeutics
  Presentation date/time:Sat., May 19, 2018, 9-9:30 a.m. CT
  Location: Salon A-1

In addition, the following Intellia collaborators will highlight aspects of their research efforts with the Company:

• “Clinical Gene Editing Programs”
  Presenter: Beverly Davidson, Ph.D., chief scientific strategy officer, Children's Hospital of Philadelphia (CHOP); director, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, CHOP; Arthur V. Meigs Chair in Pediatrics, CHOP; and professor, Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
  Session: Pre-Meeting Program – Gene Editing Workshop
  Presentation date/time:Tue., May 15, 11 a.m.-12 p.m. CT
  Location: Continental B

• “TCR Gene Transfer and TCR Gene Editing”
  Presenter: Chiara Bonini, M.D., Ph.D., full professor, Università Vita-Salute San Raffaele; deputy director, Division of Immunology, Transplantation and Infectious Diseases; and head, Experimental Hematology Unit, Ospedale San Raffaele, Italy
  Session: 100 Immune Responses to Cell and Gene Therapies, Mechanisms, Biomarkers and Therapeutic Interventions
  Presentation date/time:Wed., May 16, 2018, 8-8:30 a.m. CT
  Location: International Ballroom North

Abstracts will become available on the ASGCT website on Mon., April 30^th, at 11 a.m. CT.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; follow us on Twitter @intelliatweets.

Forward-Looking Statements

This press release contains "forward-looking statements" of Intellia within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding our ability to advance and expand the CRISPR/Cas9 technology to develop into human therapeutic products, as well as our CRISPR/Cas9 intellectual property portfolio; our ability to achieve stable or effective genome editing with a single treatment dose; the potential timing and advancement of our preclinical studies, including continuing non-human primate studies, and clinical trials; our ability to replicate results achieved in our preclinical studies in any future studies, including human clinical trials; the potential development of ex vivo cell therapeutics of all types using CRISPR/Cas9 technology; our ability to commence IND-enabling studies of a lead TTR development candidate by mid-2018 and subsequently submitting an Investigational New Drug application; our intent to present additional data for organs beyond the liver, additional insertion/repair data, and preclinical data in support of our first ex vivo programs on immuno-oncology and autoimmune/inflammation indications during 2018; our ability to nominate a development candidate for a second indication by late 2018; the intellectual property position and strategy of Intellia’s licensors; actions by government agencies; the impact of our collaborations on our development programs; the potential timing of regulatory filings regarding our development programs; the potential commercialization opportunities, including value and market, for product candidates; our expectations regarding our uses of capital, expenses, future accumulated deficit and other 2018 financial results; and our ability to fund operations through mid-2020. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain our intellectual property position; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for our product candidates; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies will be predictive of future results in connection with future studies; and the risk that Intellia’s collaborations with Novartis or Regeneron or its other ex vivo collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia Therapeutics undertakes no duty to update this information unless required by law.

Intellia Contacts:

Media:
Jennifer Mound Smoter
Senior Vice President
External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com

Lynnea Olivarez
Associate Director
External Affairs & Communications
+1 956-330-1917
lynnea.olivarez@intelliatx.com

Investors:
Lindsey Trickett
Vice President
Investor Relations
+1 857-285-6211
lindsey.trickett@intelliatx.com

Source: Intellia Therapeutics, Inc.